Subscribe
shutterstock_1436567156_jonathan_weiss
Jonathan Weiss / Shutterstock.com
22 March 2022AmericasMuireann Bolger

Takeda, Arbor aim to stop Turkish copies of high blood pressure drug

Takeda Pharmaceutical and Arbor Pharmaceuticals are seeking to block Turkey-based EastPharma from releasing a  generic version of  the blockbuster high blood pressure medication, Edarbi (azilsartan).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Genevant signs $600m liver fibrosis deal with Takeda
18 March 2021   Genevant Sciences has entered into a licence agreement for Takeda to develop and market a new liver fibrosis treatment.
Generics
Class-action accuses Takeda of ‘pay-for-delay’ deal with Par
1 July 2021   Takeda Pharmaceuticals organised a pay-for-delay deal with Par Pharmaceuticals to prevent a generic version of its constipation treatment from releasing, according to a complaint submitted to the US District Court for the District of Massachusetts.
Americas
Third Circuit backs pharma firm in antitrust clash
13 December 2022   Years-long dispute centred on treatment for gastroesophageal reflux disease | Case invited questions concerning Noerr-Pennington doctrine and immunity | Takeda | Zydus.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Big Pharma
Genevant signs $600m liver fibrosis deal with Takeda
18 March 2021   Genevant Sciences has entered into a licence agreement for Takeda to develop and market a new liver fibrosis treatment.
Generics
Class-action accuses Takeda of ‘pay-for-delay’ deal with Par
1 July 2021   Takeda Pharmaceuticals organised a pay-for-delay deal with Par Pharmaceuticals to prevent a generic version of its constipation treatment from releasing, according to a complaint submitted to the US District Court for the District of Massachusetts.
Americas
Third Circuit backs pharma firm in antitrust clash
13 December 2022   Years-long dispute centred on treatment for gastroesophageal reflux disease | Case invited questions concerning Noerr-Pennington doctrine and immunity | Takeda | Zydus.

More on this story

Big Pharma
Genevant signs $600m liver fibrosis deal with Takeda
18 March 2021   Genevant Sciences has entered into a licence agreement for Takeda to develop and market a new liver fibrosis treatment.
Generics
Class-action accuses Takeda of ‘pay-for-delay’ deal with Par
1 July 2021   Takeda Pharmaceuticals organised a pay-for-delay deal with Par Pharmaceuticals to prevent a generic version of its constipation treatment from releasing, according to a complaint submitted to the US District Court for the District of Massachusetts.
Americas
Third Circuit backs pharma firm in antitrust clash
13 December 2022   Years-long dispute centred on treatment for gastroesophageal reflux disease | Case invited questions concerning Noerr-Pennington doctrine and immunity | Takeda | Zydus.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York